Drug Discovery faces a rising number of projects that demand the generation of cellular reagents with controlled or lower target protein expression. Here, we have tested and optimized several ...
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...